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Abstract
Discontinuation effects following cessation of 12 and 24 wk of pregabalin treatment for generalized anxiety
disorder (GAD) were evaluated in a placebo- and lorazepam-controlled, randomized, double-blind, multicentre
trial conducted in 16 countries. The study design consisted of two 12-wk treatment periods (periods 1 and 2),
each followed by a 1-wk taper and two post-discontinuation assessments, one immediately following
the taper and one 1-wk post-taper. Patients were assigned to receive an initially ﬂexible dose of pregabalin
450–600mg/d, pregabalin 150–300mg/d, or lorazepam 3–4mg/d for 6 wk; responders continued ﬁxed-dose
therapy for 6 additional weeks. Patients entering period 2 continued on the same ﬁxed dose or switched to
placebo. Discontinuation effects were evaluated with the Physician Withdrawal Checklist (PWC) and reported
discontinuation-emergent signs and symptoms. Rebound anxiety was measured with the Hamilton Anxiety
Rating Scale. GAD symptoms improved with all treatments and improvements were maintained over 12 and
24 wk. Low levels of discontinuation symptoms were evident in all treatment groups. For patients who received
active treatment during both periods, mean (95% conﬁdence interval) increases on the PWC from last visit on
active treatment to the second post-discontinuation assessment were: pregabalin 450–600mg/d: 2.8 (1.6–3.9),
pregabalin 150–300mg/d: 1.7 (0.7–2.8), lorazepam 3–4mg/d: 2.2 (1.0–3.5). Rates of rebound anxiety were also
low at both 12 and 24 wk (0–6%). This suggests that risk of discontinuation symptoms and rebound anxiety
are low for pregabalin after 12 and 24 wk of treatment.
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Introduction
Generalized anxiety disorder (GAD) is a chronic and dis-
abling condition with an estimated 12 month prevalence
of ∼2% in Europe (Lieb et al., 2005) and ∼3% in the
United States (Kessler et al., 2005). The probability of
full recovery from GAD is less than 40%, and among indi-
viduals whose symptoms remit, there is a high likelihood
of recurrence (Yonkers et al., 1996; Rodriguez et al., 2006).
Functional impairments in those with pure GAD (without
comorbidity) is comparable to pure major depressive dis-
order and other mood disorders and, if not successfully
treated, disability is similar to that seen in chronic medical
illnesses (Kessler et al., 1999, 2001; Wittchen et al., 2000;
Grant et al., 2005; Hoffman et al., 2008).
A variety of treatment options currently exist for
GAD, including selective serotonin reuptake inhibitors,
serotonin-noradrenaline reuptake inhibitors, benzodiaze-
pines and tricyclic antidepressants (Baldwin et al.,
2011). In Europe, as well as in some countries outside
Europe, another option is pregabalin, which has been ap-
proved for the treatment of GAD in adults and is now in-
cluded as a ﬁrst-line treatment option in guidelines from
the World Federation of Societies of Biological Psychiatry
(Bandelow et al., 2008). The efﬁcacy and safety of prega-
balin for the treatment of GAD has been demonstrated in
multiple short-term (4 to 8 wk) clinical trials (Feltner
et al., 2003; Pande et al., 2003; Pohl et al., 2005; Rickels
et al., 2005; Montgomery et al., 2006; Kasper et al., 2009).
Given the chronicity of GAD, the safety and efﬁcacy
of long-term pharmacotherapy is of particular clinical rel-
evance. Whereas short-term efﬁcacy trials evaluate the
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degree of early treatment response and initial tolerability,
long-term trials evaluate the ability of anxiolytic
treatments to sustain initial response and achieve sympto-
matic remission. Additional important goals of long-term
trials include evaluating the optimal duration of treat-
ment and the degree to which medication discontinuation
is associated with symptoms and/or anxiety recurrence.
When pregabalin is discontinued, a taper of at least
1 wk is recommended to minimize discontinuation symp-
toms (Pﬁzer Inc, New York, NY, USA). To evaluate such
potential discontinuation effects and to determine main-
tenance of treatment response following discontinuation
of a drug, double-blind placebo-substitution studies are
indicated.
Only a few double-blind placebo-substitution studies
have been conducted in the treatment of GAD. These
include studies of paroxetine (Stocchi et al., 2003), escita-
lopram (Allgulander et al., 2006), duloxetine (Davidson
et al., 2008) and venlafaxine (Rickels et al., 2010). Despite
the extensive literature on the short-term efﬁcacy of high
potency benzodiazepines in the treatment of GAD (Mitte
et al., 2005) and the continued common use of benzodia-
zepines in the treatment of GAD (Baldwin et al., 2012),
no double-blind placebo-substitution studies have been
published in which patients have been prospectively trea-
ted with a benzodiazepine for GAD. However, studies
have recruited patients reporting long-term naturalistic
use of benzodiazepines, or who have documented benzo-
diazepine dependence. These studies report high rates of
discontinuation symptoms with long-term (>6 months)
use of benzodiazepines, particularly if discontinuation is
abrupt (Rickels et al., 1983, 1988, 1990).
The goal of the current study was to evaluate the fre-
quency and severity of discontinuation and rebound
symptoms associated with short- (12 wk) and long-
(24 wk) term treatment with two doses of pregabalin in
patients with moderate-to-severe GAD who responded
to 6 wk of acute treatment. To evaluate discontinuation
symptoms relative to previous studies of discontinuation
or withdrawal symptoms, the study design also included
a group of patients who received an established com-
parator drug (lorazepam) as active control. Secondary
aims of the study were to characterize descriptively the
long-term safety and efﬁcacy of pregabalin, the latter
in terms of the maintenance of improvement among
patients who respond to short-term treatment with
pregabalin.
Experimental procedures
Study design
This was a 24-wk placebo- and lorazepam-controlled,
randomized, double-blind, multicentre trial for the evalu-
ation of the discontinuation effects of pregabalin in the
treatment of GAD. The study consisted of an initial
screening and baseline assessment followed by two con-
secutive 12-wk treatment periods (Fig. 1). Eligible patients
were randomly assigned at baseline to a sequence of treat-
ments during treatment period 1 and treatment period 2:
(1) pregabalin high dose followed by pregabalin high
dose, (2) pregabalin high dose followed by placebo,
(3) pregabalin low dose followed by pregabalin low
dose, (4) pregabalin low dose followed by placebo,
450–600 mg/d (n = 154)  PGBH
Pregabalin 450–600 mg/d
Placebo (n = 52)n = 206 
PGBH
1 wk
Taper*
Taper*
Taper*
150–300 mg/d (n = 154)
PGBL
Pregabalin 150–300 mg/d
n = 206 Placebo (n = 52)
1 wk
1 wk
PGBL
3–4 mg/d (n = 153)
LOR LOR
Lorazepam 3–4 mg/d
n = 203 Placebo (n = 50) PBO
Period 1
Flexible dose (weeks 1–6),
Fixed dose (weeks 7–12),
Double-blind, 12 wk 
Screen
1 wk
 Period 2
Fixed dose, double-blind
12 wk
 Follow-up
1 wk
Taper
1 wk
PGBH
PBO
PGBL
PBO
LOR
Fig. 1. Study design. *Discontinuation symptoms were evaluated both at the end of the 1 wk taper (week 13) and at a follow-up
visit 1 wk later (week 14). PGBH, pregabalin high dose (450–600mg/d); PGBL, pregabalin low dose (150–300mg/d); LOR, lorazepam
3–4mg/d; PBO, placebo.
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(5) lorazepam followed by lorazepam, or (6) lorazepam
followed by placebo. The randomized scheme was struc-
tured for a 1:1:1 ratio assignment based on the treatment
period 1 group (pregabalin high dose, pregabalin low
dose, lorazepam); 25% of patients from each medication
group were randomized to discontinue active medication
after treatment period 1 and receive placebo during treat-
ment period 2. The allocation of 25% of patients to
placebo and 75% to continued treatment was done so
that discontinuation effects after both 12-wk and 24-wk
exposure to pregabalin could be evaluated. The ex-
pectation was that it would be more difﬁcult to retain
patients for 24 wk, so a larger percentage was allocated
to continue active treatment in treatment period 2.
Treatment period 1 was 12 wk in duration. At week 6,
responders, deﬁned as patients with a Clinical Global
Impressions-Improvement (CGI-I) (Guy, 1976) score of
1 or 2, continued with treatment for an additional 6 wk;
non-responders exited the study. The CGI-I was used to
identify non-responders because the CGI-I most closely
captures a clinical decision-making process by a psycho-
pharmacologist. At the end of week 12, 75% of patients
in each group continued on to treatment period 2 with
the same treatment. The other 25% of patients in each
group were tapered to placebo so that discontinuation
symptoms could be evaluated. Following the double-
blind taper, these patients received double-blind placebo
in treatment period 2 (12 wk). The patients who con-
tinued with active medication during treatment period
2 underwent a 1-wk double-blind taper beginning at
week 25 (taper of treatment period 2) to evaluate dis-
continuation symptoms. Any patients who were discon-
tinued from active medication at any other point during
the study also underwent a 1-wk double-blind taper off
treatment to evaluate discontinuation symptoms.
The study was conducted from 13 May 2009 to
2 April 2012, at 60 centres in 16 countries (Argentina,
Austria, Costa Rica, Croatia, Czech Republic, Finland,
Greece, Guatemala, Indonesia, Lithuania, Mexico,
Russian Federation, Serbia, Slovenia, Spain and Turkey).
At all centres, the study protocol was approved by
an Institutional Review Board or Ethics Committee.
Written informed consent was obtained from all patients.
The study was conducted according to the principles
of the Declaration of Helsinki and Good Clinical Prac-
tice Guidelines and is registered on Clinicaltrials.gov
(NCT00624780).
Study treatments
Following the European product label recommendations
for pregabalin (Pﬁzer Inc., 2009), treatment was initiated
with a 150mg/d starting dose in both the low- and high-
dose pregabalin groups. The lorazepam starting dose was
2mg/d. Upward dose escalation occurred during the ﬁrst
3 wk. Following dose escalation, patients received prega-
balin 450–600mg/d (high dose), pregabalin 150–300mg/d
(low dose) or lorazepam 3–4mg/d, with ﬂexible-dose
treatment within the speciﬁed ranges during the ﬁrst
6 wk based on tolerability and clinical improvement.
Patients who showed a clinical response (CGI-I score of
1 or 2) at week 6 continued treatment; those who had a
CGI-I score >2 at week 6 were discontinued from the
study. During the second half of treatment period 1,
patients were maintained on a ﬁxed-dose treatment at
the ﬁnal dosage achieved during the initial 6-wk ﬂexible
dosage phase. Study drug was administered twice per
day (in equal doses) and was blinded using a double-
dummy method. Patients entering treatment period 2
either continued on the same ﬁxed dose or switched to
placebo, according to the randomization scheme.
The 1-wk double-blind taper schedule was generally
consistent with product labelling and was intended
to minimize the risk that patients could potentially ex-
perience severe drug discontinuation symptoms. Any
patients experiencing severe discontinuation symptoms
during the taper periods and up to 7 d afterwards
could be provided with a more gradual ‘rescue’ taper,
extending the taper to 4 wk while maintaining the
blind. This same taper schedule and rescue taper protocol
was used for all patients, regardless of when treatment
was discontinued.
Study population
Eligible patients, recruited from the clinic population,
clinic referrals or from advertisements, were aged
18 to 65 yr with a primary diagnosis of GAD at baseline.
Additional inclusion criteria were a Hamilton Anxiety
Rating Scale (HAM-A) (Hamilton, 1960) total score 514
and a Hamilton Rating Scale for Depression (HAM-D)
(Hamilton, 1959) item 1 score 42 at both screening
and baseline visits (the baseline assessment occurred
∼4–10 d following screening). Patients with a current or
past diagnosis of any other Diagnostic and Statistical
Manual of Mental Disorders (DSM)-IV Axis I disorder
(American Psychiatric Association, 2000) besides GAD
were excluded (with the exception of current or past diag-
nosis of depression not otherwise speciﬁed, speciﬁc pho-
bia, somatization disorder, nicotine or caffeine abuse/
dependence or past history of major depressive disorder,
social phobia, panic disorder or eating disorder). Indivi-
duals were also excluded from the study if they reported
daily (55 d/wk) use of benzodiazepines for treating GAD
during the 3 months prior to screening, a history of failed
treatment with any benzodiazepine (determined by a
judgment of the clinical investigator who took into ac-
count reported dosage and duration) or any reported
prior exposure to pregabalin. Those individuals taking a
benzodiazepine for less than 5 d/wk could be included
if they stopped taking the benzodiazepine 2 wk prior to
baseline. No benzodiazepine use was allowed during
the study. Additional exclusion criteria were pregnancy/
lactation, suicide risk, current use of psychotropic
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medication that could not be discontinued prior to base-
line, positive urine test results at screening for potential
drug abuse or illegal drugs, positive alcohol breathalyzer
test at screening or any serious or unstable medical
condition assessed at screening.
Assessment of discontinuation symptoms
The primary measure of discontinuation symptoms
was the Physician Withdrawal Checklist (Rickels et al.,
1990). The PWC is a 20-item physician-rated interview
(total score range 0–60) that measures the presence of
anxiolytic drug discontinuation-related signs and symp-
toms in the following areas: gastrointestinal, mood,
sleep, motor, somatic, perception and cognition. The
PWC was administered at baseline and weeks 12, 13, 14,
24, 25 and 26. The 13- and 14-wk assessments and the
25- and 26-wk assessments corresponded to the end of
the 1-wk taper and 1 wk after completing the taper for
treatment periods 1 and 2, respectively, and were conduc-
ted to evaluate discontinuation symptoms by calculating
change in PWC total scores from last visit on active treat-
ment (week 12 or 24) to these post-discontinuation visits.
The incidence of spontaneously reported treatment-
emergent adverse events occurring during the discontinu-
ation weeks (i.e. from the ﬁrst day of the ﬁrst taper dose
through the last available visit in either the taper week
or the week following taper) was examined as a second-
ary measure of Discontinuation-Emergent Signs and
Symptoms (DESS). These adverse events were evaluated
for the taper of treatment periods 1 and 2. DESS were
deﬁned as newly developed adverse events or worsening
of existing adverse events reported during the taper
periods.
The HAM-A total score was used to evaluate rebound
anxiety. This was deﬁned as a HAM-A total score higher
during the discontinuation assessments (weeks 13, 14, 25
and 26) compared with baseline.
Efﬁcacy measures
The primary efﬁcacy measure was the HAM-A.
Secondary efﬁcacy measures consisted of the CGI-I and
Clinical Global Impression-Severity (CGI-S) scales (Guy,
1976). The HAM-A and CGI-S were administered by
trained clinicians (study investigators) at baseline and
weeks 3, 6, 9, 12, 13, 14, 15, 18, 21, 24, 25 and 26. The
CGI-I, also administered by trained clinicians, was
obtained weekly from weeks 1 to 6, and then at weeks
9, 12, 13, 14, 15, 18, 21, 24, 25 and 26.
Safety measures
Safety was evaluated through blood chemistry, haema-
tology and urinalysis (assessed at baseline and week 26)
and by vital signs (assessed at baseline and weeks 1,
3, 6, 9, 12, 13, 14, 24, 25 and 26). Spontaneously re-
ported or observed adverse events (all-causality and
treatment-related) were recorded at each study visit. All
adverse events were categorized in terms of their severity
by the treating clinician. Study discontinuation owing
to adverse events was also speciﬁed as a measure of
safety/tolerability.
Statistical methods
Sample size determination was based on an expected
discontinuation rate of 50% by the end of treatment
period 1. A sample size of 75 patients per group was cal-
culated based on an estimation of the true mean change
from baseline to within 2.0 units of the PWC (assuming
a standard deviation of 7.8 units) using a 95% conﬁdence
interval (CI) with 90% coverage probability.
The primary sample for analyses of discontinuation
symptoms and efﬁcacy included all randomized patients
who had at least one discontinuation week or efﬁcacy
assessment, and who were not major protocol violators.
The primary safety sample was deﬁned as all randomized
patients who received at least one dose of study
medication.
To evaluate potential discontinuation effects, one sam-
ple analysis was conducted, consisting of mean changes
(and associated 95% CI) in the PWC total scores from
the visit prior to the start of tapering to the end of
weeks 1 and 2 of each taper period (weeks 13 and 14
for treatment period 1; weeks 25 and 26 for treatment
period 2). DESS events and the percent of patients with
rebound anxiety were summarized by treatment group
and for each of the 2 wk following the initiation of the
tapers. Efﬁcacy of continued treatment was evaluated
descriptively for each treatment group in terms of mean
changes (and 95% CIs) in the HAM-A and CGI-S from
baseline to week 12 and baseline to week 24. CGI-I scores
at weeks 12 and 24 (last observation carried forward)
were similarly evaluated. Safety analyses consisted of
reporting the proportion of patients with treatment-
emergent adverse events for each treatment.
Results
Patient characteristics and disposition
A total of 816 patients were screened for the study (Fig. 2).
Of those screened, 615 patients met study entry criteria
and were randomized to one of two pregabalin dose
ranges: 450–600mg/d (n=206) or 150–300mg/d (n=206);
or lorazepam 3–4mg/d (n=203). A total of 615 patients
received at least one dose of study treatment and consti-
tuted the safety sample. There were 463 (75.3%) patients
who completed treatment period 1 and 366 (59.5%) who
completed treatment period 2. Among patients who
discontinued treatment period 1 early or entered the
taper period following treatment period 1, a rescue
taper was used for four patients assigned to pregabalin
450–600mg/d, six patients assigned to pregabalin
150–300mg/d and two patients assigned to lorazepam
688 S. Kasper et al.
3–4mg/d. Among those who discontinued treatment
period 2 early or entered the taper period following
treatment period 2, a rescue taper was used for six
patients who received pregabalin 450–600mg/d through-
out both treatment periods, zero patients who received
pregabalin 450–600mg/d during treatment period 1 and
placebo during treatment period 2, ﬁve patients who re-
ceived pregabalin 150–300mg/d throughout both treat-
ment periods, six patients who received pregabalin
150–300mg/d during treatment period 1 and placebo
during treatment period 2, eight patients who received
lorazepam 3–4mg/d throughout both treatment periods
and two patients who received lorazepam 3–4mg/d
during treatment period 1 and placebo during treatment
period 2.
Patients in the study sample had a mean age of ∼42 yr
(range 18–65); 60.8% of patients were female and 82.4%
were white (Table 1). The mean duration since the onset
of GAD symptoms was ∼2.3 yr (range 0–36.6). Patients
in the six treatment groups in treatment period 2 did
not differ signiﬁcantly on available baseline character-
istics or median treatment duration.
Discontinuation symptoms and rebound anxiety
Increases in PWC total scores from the last visit in treat-
ment period 1 to the ﬁrst and second weeks following
taper were small (Table 2). Similarly, in the groups who
remained on active treatment throughout both treatment
periods, small increases in PWC scores were apparent
from the last visit of the second treatment period to the
ﬁrst and second weeks following the initiation of the
taper of treatment period 2. Mean change on the PWC
Screened
n = 816
PGB 450–600 mg/d
n = 206
PGB 450–600 mg/d
n = 121
PGB 150–300 mg/d
n = 112
PBO*
n = 39
PBO*
n = 38
PBO*
n = 39
LOR 3–4 mg/d
n = 114
PGB 150–300 mg/d
n = 206
12 wk of DB treatment
12 wk of DB treatment
Completed 24 wk
n = 106
Completed taper, 1 wk
n = 102
Completed taper, 1 wk
n = 27
Completed taper, 1 wk
n = 89
Completed taper, 1 wk
n = 26
Completed taper, 1 wk
n = 93
Completed taper, 1 wk
n = 29
Completed 24 wk
n = 28
Completed 24 wk
n = 94
Completed 24 wk
n = 27
Completed 24 wk
n = 95
Completed 24 wk
n = 30
12 wk of DB treatment 12 wk of DB treatment 12 wk of DB treatment 12 wk of DB treatment 12 wk of DB treatment
LOR 3–4 mg/d
n = 203
12 wk of DB treatment
DB taper, 1 wk DB taper, 1 wk DB taper, 1 wk
12 wk of DB treatment
Randomized
n = 615
Discontinued n = 52 (33.8%)
Adverse event n = 13 (8.4%)
Lack of efficacy n = 8 (5.2%)
Miscellaneous n = 31 (20.1%)
Discontinued n = 25 (48.1%)
Adverse event n = 9 (17.3%)
Lack of efficacy n = 3 (5.8%)
Miscellaneous n = 13 (25.0%)
Discontinued n = 65 (42.2%)
Adverse event n = 22 (14.3%)
Lack of efficacy n = 12 (7.8%)
Miscellaneous n = 31 (20.1%)
Discontinued n = 26 (50.0%)
Adverse event n = 6 (11.5%)
Lack of efficacy n = 10 (19.2%)
Miscellaneous n = 10 (19.2%)
Discontinued n = 60 (39.2%)
Adverse event n = 13 (8.5%)
Lack of efficacy n = 14 (9.2%)
Miscellaneous n = 33 (21.6%)
Discontinued n = 21 (42.0%)
Adverse event n = 7 (14.0%)
Lack of efficacy n = 3 (6.0%)
Miscellaneous n = 11 (22.0%)
Fig. 2. Patient disposition. *Represents the number of patients who received placebo after completing 12 wk of treatment. A larger
number of patients were randomized at baseline to receive placebo at the end of period 1 in the pregabalin 450–600mg group
(n=52), the pregabalin 150–300mg group (n=52), and the lorazepam 3–4mg group (n=50); however, the number who actually
received placebo was smaller owing to premature discontinuation. DB, double-blind; PGB, pregabalin; LOR, lorazepam 3–4mg/d;
PBO, placebo.
Table 1. Baseline characteristics and treatment duration
(treatment period 1 group)
Pregabalin
(450–600mg/d)
(n=206)
Pregabalin
(150–300mg/d)
(n=206)
Lorazepam
(3–4mg/d)
(n=203)
Male, n (%) 87 (42.2) 73 (35.4) 81 (39.9)
Race, n (%)
White 176 (85.4) 165 (80.1) 166 (81.8)
Black 0 (0) 0 (0) 1 (0.5)
Asian 14 (6.8) 22 (10.7) 22 (10.8)
Other 16 (7.8) 19 (9.2) 14 (6.9)
Age, yr
Mean (S.D.) 42.4 (11.5) 40.5 (12.3) 42.6 (11.2)
Range 18–64 18–65 19–65
Duration of illness, yr
Mean (S.D.) 2.2 (4.4) 2.1 (4.3) 2.4 (4.3)
Range 0–28 0–28 0–37
Treatment duration, d
Median (S.D.) 139.4 (55.1) 133.2 (58.3) 136.7 (59.4)
Range 1–233 2–216 4–216
S.D., standard deviation.
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among the patients who received placebo during treat-
ment period 2 was also small.
Among the subgroup of patients who discontinued
active treatment at the end of treatment period 1, DESS
were reported by a total of 21 (36.2%) who received preg-
abalin 450–600mg/d, 17 (32.7%) who received pregabalin
150–300mg/d and 17 (32.7%) who received lorazepam
3–4mg/d during the 2 wk following the initiation of the
taper of treatment period 1 (Table 3). Anxiety, headache,
insomnia and nausea were the only DESS that occurred in
55% of patients in any treatment group during treatment
period 1. In the 2 wk following the initiation of the
taper of treatment period 2, DESS events were reported
by 22.3–31.2% of patients receiving any active medication
during both treatment periods (Table 3), and by
13.3–31.0% of those receiving placebo during treatment
period 2. Anxiety, headache and insomnia were the
only DESS that occurred in 55% of patients in any of
the treatment groups during treatment period 2.
The incidence of rebound anxiety was low across
active treatment groups in patients who discontinued ac-
tive treatment after treatment period 1 (range 1.9–5.2%)
and also in patients who discontinued active treatment
after treatment period 2 (range 0–6%) (Table 4).
Efﬁcacy
Substantial improvements in anxiety and illness severity
were observed in all three treatment groups at the end
of treatment period 1 (Table 5). Mean HAM-A changes
from baseline to week 12 (LOCF) ranged from −16.0 to
−17.4 across treatment groups. For patients continuing
into treatment period 2, improvements in anxiety symp-
toms were maintained for those who remained on active
medication during treatment period 2 as well as for
patients who switched from active drug to placebo for
treatment period 2 (Table 5). Mean HAM-A changes
from baseline to week 24 (LOCF) ranged from −14.9 to
−19.0 over the six treatment groups. Results for CGI-S
and CGI-I scores also showed that improvements during
the initial 12-wk treatment period were maintained over
the course of the second 12-wk treatment period, both
for patients who remained on active drug and for those
switched to placebo (Table 5).
Safety
Among patients assigned to receive active drug for 24 wk,
treatment-emergent adverse events were reported by
78.6% (121/154) who received pregabalin 450–600mg/d,
78.6% (121/154) receiving pregabalin 150–300mg/d and
75.2% (115/153) of patients receiving lorazepam. Severe
adverse events occurred in 17.5% (27/154) of patients trea-
ted with pregabalin 450–600mg/d, 13.6% (21/154) treated
with pregabalin 150–300mg/d and 14.4% (22/153) treated
with lorazepam. The most common adverse events re-
ported were headache, dizziness, insomnia and somnol-
ence (Table 6). Discontinuations owing to adverse
events at any time while on active drug over the course
of 6 months occurred for 8.4% of patients receiving preg-
abalin 450–600mg/d, 14.3% receiving pregabalin 150–300
mg/d and 8.5% receiving lorazepam. One death occurred
Table 2. Discontinuation symptoms following treatment period 1 (weeks 1 to 12) and treatment period 2 (weeks 13 to 24): mean change
in PWC
Mean changea
(95% CI) in PWC, n
Pregabalin
(450–600mg/d)
Pregabalin
(150–300mg/d)
Lorazepam
(3–4mg/d)
Discontinuation symptoms following treatment period 1b
Week 1 after initiating taperc n=58 n=52 n=49
1.9 (−0.1, 3.8) 1.4 (0.2, 2.7) 2.3 (0.4, 4.2)
Week 2 after initiating taperc n=54 n=49 n=44
2.1 (0.4, 3.7) 2.0 (0.5, 3.6) 1.6 (−0.3, 3.6)
Discontinuation symptoms following treatment period 2d
Week 1 after initiating taperc n=109 n=93 n=99
1.7 (0.7, 2.6) 1.1 (0.4, 1.9) 3.0 (1.7, 4.4)
Week 2 after initiating taperc n=106 n=84 n=93
2.8 (1.6, 3.9) 1.7 (0.7, 2.8) 2.2 (1.0, 3.5)
a Change is measured from the last visit during the respective treatment period to the week 1 and week 2 visits following taper
initiation after each treatment period.
b Includes all patients who discontinued between weeks 9–15, or who switched to placebo at the end of week 12, and had a correspond-
ing assessment in the 2 wk following initiation of the taper.
c The taper period was 1 wk long.
d Includes all patients who either completed the study or discontinued after week 15, and had a corresponding assessment in the 2 wk
following taper initiation.
PWC, Physician Withdrawal Checklist, total score; CI, conﬁdence interval.
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during the study. The patient had been randomized to re-
ceive pregabalin 150–300mg/d in both treatment groups.
The cause of death was reported as metastasis of
unknown origin and was not considered related to the
study drug. The patient also had infectious disease of
unknown origin at the time of death.
No clinically meaningful changes in laboratory test
values were evident for patients in any of the treatment
groups. A similarly small proportion of patients had
vital signs that met the criteria for abnormality (e.g.
increased systolic blood pressure), but none of the values
were considered to be of clinical concern.
Table 3. Discontinuation emergent signs and symptoms (DESS) occurring in 55% of patients after 12 and 24 wk of treatment
DESSa during 2 wk following taperb initiation after treatment period 1c
PGBH PGBL LOR
(n=58) (n=52) (n=52)
Patients with DESS, n (%) 21 (36.2) 17 (32.7) 17 (32.7)
Anxiety 3 (5.2) 0 (0.0) 2 (3.8)
Dizziness 3 (5.2) 0 (0.0) 0 (0.0)
Headache 3 (5.2) 4 (7.7) 1 (1.9)
Insomnia 6 (10.3) 4 (7.7) 10 (19.2)
Nausea 4 (6.9) 3 (5.8) 2 (3.8)
DESSa during 2 wk following taperb initiation after treatment period 2d
PGBHPGBH PGBHPBO PGBLPGBL PGBLPBO LORLOR LORPBO
(n=109) (n=30) (n=94) (n=29) (n=100) (n=30)
Patients with DESS, n (%) 34 (31.2) 4 (13.3) 21 (22.3) 9 (31.0) 28 (28.0) 4 (13.3)
Anxiety 7 (6.4) 1 (3.3) 4 (4.3) 0 (0.0) 8 (8.0) 0 (0.0)
Headache 5 (4.6) (0.0) 3 (3.2) 2 (6.9) 2 (2.0) (0.0)
Insomnia 13 (11.9) 1 (3.3) 8 (8.5) 2 (6.9) 6 (6.0) 2 (6.7)
a DESS adverse events are a subset of Treatment Emergent Signs and Symptoms and are deﬁned as those spontaneously reported
adverse events that developed or existed prior to but worsened during the 2 wk following taper initiation (i.e. weeks 13 and 14 for
those who discontinued at week 12 and weeks 25 and 26 for those who discontinued at week 24).
b The taper period was 1 wk long.
c All patients who discontinued between weeks 9–15, or who switched to placebo at the end of week 12, and had a corresponding
discontinuation week assessment.
d All patients who either completed the study or discontinued after week 15, and had a corresponding assessment in the 2 wk following
taper initiation.
DESS, discontinuation-emergent signs and symptoms; PGBH, pregabalin high dose (450–600mg/d); PGBL, pregabalin low dose
(150–300mg/d); LOR, lorazepam 3–4mg/d.
Table 4. Rebound anxiety after treatment periods 1 and 2
Pregabalin
(450–600mg/d)
Pregabalin
(150–300mg/d)
Lorazepam
(3–4mg/d)
Rebound anxietya during 2 wk following taperb initiation, n/N (%)
After treatment period 1c 3/58 (5.2) 1/52 (1.9) 2/48 (4.2)
After treatment period 2d 4/109 (3.7) 0/94 (0) 6/100 (6.0)
a Rebound anxiety is deﬁned as a Hamilton Anxiety Rating Scale total score greater than the baseline score during either of the 2 wk
following taper initiation.
b The taper period was 1 wk long.
c All patients who discontinued between weeks 9–15, or who switched to placebo at the end of week 12, and had a corresponding
assessment in the 2 wk following taper initiation.
d All patients who either completed the study or discontinued after week 15, and had a corresponding assessment in the 2 wk follow-
ing taper initiation.
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Table 5. Efﬁcacy measures at baseline, week 12, and week 24
Treatment groups during treatment period 1
PGBH PGBL LOR
HAM-A total score
Baseline (95% CI) n=197 n=183 n=188
25.3 (24.7, 26.0) 24.9 (24.3, 25.4) 24.5 (23.9, 25.1)
Week 12 mean change (95% CI) (LOCF) n=194 n=180 n=185
−17.4 (−18.5, −16.4) −16.0 (−17.1, −14.9) −16.7 (−17.8, −15.5)
CGI-Severity score
Baseline (95% CI) n=197 n=183 n=188
4.6 (4.5, 4.7) 4.5 (4.4, 4.6) 4.4 (4.3, 4.5)
Week 12 mean change (95% CI) (LOCF) n=195 n=181 n=186
−2.3 (−2.5, −2.1) −2.1 (−2.2, −1.9) −2.1 (−2.2, −1.9)
CGI-Improvement
Week 12 mean score (95% CI) (LOCF) n=197 n=183 n=188
1.9 (1.7, 2.0) 1.9 (1.7, 2.0) 1.9 (1.8, 2.1)
Treatment groups during treatment period 2
PGBHPGBH PGBHPBO PGBLPGBL PGBLPBO LORLOR LORPBO
(n=117) (n=37) (n=103) (n=37) (n=106) (n=37)
HAM-A total score
Baseline (95% CI) 25.6 (25.0, 26.3) 24.6 (23.0, 26.1) 24.8 (24.0, 25.5) 25.1 (23.8, 26.4) 24.7 (23.8, 25.5) 24.1 (22.8, 25.5)
Week 24 mean change (95% CI) (LOCF) −18.7 (−20.0, −17.3) −17.5 (−19.8, −15.2) −18.2 (−19.5, −17.0) −14.9 (−17.6, −12.3) −19.0 (−20.4, −17.6) −17.5 (−20.2, −14.7)
CGI-Severity score
Baseline (95% CI) 4.7 (4.6, 4.8) 4.5 (4.3, 4.7) 4.5 (4.4, 4.7) 4.5 (4.3, 4.8) 4.4 (4.3, 4.6) 4.5 (4.3, 4.7)
Week 24 mean change (95% CI) (LOCF) −2.4 (−2.6, −2.2) −2.3 (−2.7, −1.9) −2.4 (−2.6, −2.2) −2.0 (−2.4, −1.6) −2.5 (−2.7, −2.3) −2.2 (−2.6, −1.8)
CGI-Improvement
Week 24 mean score (95% CI) (LOCF) 1.7 (1.6, 1.9) 1.9 (1.6, 2.3) 1.6 (1.4, 1.7) 2.3 (1.8, 2.8) 1.5 (1.3, 1.7) 2.0 (1.6, 2.3)
PGBH, pregabalin high dose (450–600mg/d); PGBL, pregabalin low dose (150–300mg/d); LOR, lorazepam 3–4mg/d; HAM-A, Hamilton Anxiety Rating Scale total score; CI, conﬁdence interval;
LOCF, last observation carried forward; CGI, Clinical Global Impressions; PBO, placebo.
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Discussion
The current study is the ﬁrst to evaluate discontinuation
symptoms following long-term (6 month) pregabalin
treatment for GAD using a prospective, randomized,
double-blind, active control, placebo-substitution design
with evaluations at 12 and 24 wk. The results indicate
that, for both high- and low-dose pregabalin responders
who continued with treatment to 12 or 24 wk, there
was a low incidence of discontinuation symptoms as
measured by the PWC or by spontaneously reported
DESS during a 2-wk discontinuation evaluation at the
end of each treatment period. In addition, the incidence
of rebound anxiety was low (0–6%) and did not appear
to be related to either dose or duration of treatment.
The lack of clinically meaningful discontinuation symp-
toms or rebound anxiety for pregabalin after either
12 or 24 wk of treatment supports the utilization of a
1-wk treatment taper to manage the potential of rebound
anxiety and discontinuation symptoms with pregabalin
for the treatment of GAD.
No new safety ﬁndings regarding pregabalin were
evident in this study. There were no notable or unexpec-
ted abnormalities in vital signs or laboratory ﬁndings
during 6 months of treatment with either pregabalin or
lorazepam. Both doses of pregabalin were well-tolerated,
with minimal dose-related differences in adverse events.
However, interpreting the incidence of adverse events is
difﬁcult in the absence of a parallel placebo-control
group during the initial 12 wk of treatment.
Comparison of the discontinuation results of the cur-
rent study to other studies in the literature is difﬁcult
because the current study used a 4mg maximum dose
of lorazepam, consistent with product labelling and cur-
rent clinical practice. In contrast, previous studies often
used higher (up to 6mg/d) doses of lorazepam (Cutler
et al., 1993; Mandos et al., 1995; Feltner et al., 2003). The
lower dose used here may explain why marked discon-
tinuation effects were not observed following a 1-wk
taper off lorazepam.
Although this study was designed to assess potential
discontinuation symptoms, the efﬁcacy outcome data
Table 6. Treatment-emergent adverse events (incidence55% in any 1 treatment group)
Treatment group
Adverse event, n (%)
PGBHPGBH
(n=154)
PGBHPBO
(n=52)
PGBLPGBL
(n=154)
PGBLPBO
(n=52)
LORLOR
(n=153)
LORPBO
(n=50)
Headache 38 (24.7) 13 (25.0) 36 (23.4) 17 (32.7) 33 (21.6) 10 (20.0)
Dizziness 37 (24.0) 17 (32.7) 28 (18.2) 14 (26.9) 20 (13.1) 10 (20.0)
Insomnia 31 (20.1) 15 (28.8) 24 (15.6) 12 (23.1) 23 (15.0) 13 (26.0)
Somnolence 25 (16.2) 7 (13.5) 31 (20.1) 9 (17.3) 35 (22.9) 13 (26.0)
Nausea 17 (11.0) 7 (13.5) 12 (7.8) 8 (15.4) 18 (11.8) 7 (14.0)
Fatigue 16 (10.4) 6 (11.5) 15 (9.7) 11 (21.2) 15 (9.8) 5 (10.0)
Anxiety 15 (9.7) 6 (11.5) 10 (6.5) 1 (1.9) 19 (12.4) 5 (10.0)
Nasopharyngitis 13 (8.4) 2 (3.8) 7 (4.5) 5 (9.6) 8 (5.2) 4 (8.0)
Dry mouth 13 (8.4) 3 (5.8) 5 (3.2) 2 (3.8) 8 (5.2) 4 (8.0)
Disturbance in attention 12 (7.8) 1 (1.9) 3 (1.9) 2 (3.8) 6 (3.9) 1 (2.0)
Diarrhoea 10 (6.5) 3 (5.8) 8 (5.2) 5 (9.6) 9 (5.9) 1 (2.0)
Constipation 10 (6.5) 1 (1.9) 4 (2.6) 2 (3.8) 2 (1.3) 1 (2.0)
Back pain 9 (5.8) 1 (1.9) 1 (0.6) 0 4 (2.6) 2 (4.0)
Inﬂuenza 8 (5.2) 3 (5.8) 7 (4.5) 0 7 (4.6) 0
Tension 8 (5.2) 1 (1.9) 4 (2.6) 0 2 (1.3) 1 (2.0)
Sedation 6 (3.9) 2 (3.8) 5 (3.2) 0 10 (6.5) 1 (2.0)
Decreased appetite 6 (3.9) 1 (1.9) 3 (1.9) 4 (7.7) 6 (3.9) 3 (6.0)
Irritability 6 (3.9) 1 (1.9) 4 (2.6) 2 (3.8) 8 (5.2) 1 (2.0)
Paraesthesia 6 (3.9) 0 3 (1.9) 3 (5.8) 5 (3.3) 2 (4.0)
Myalgia 5 (3.2) 4 (7.7) 4 (2.6) 2 (3.8) 9 (5.9) 1 (2.0)
Tremor 5 (3.2) 2 (3.8) 1 (0.6) 3 (5.8) 6 (3.9) 0
Weight increased 5 (3.2) 1 (1.9) 7 (4.5) 3 (5.8) 4 (2.6) 0
Generalized anxiety
disorder
4 (2.6) 2 (3.8) 9 (5.8) 2 (3.8) 7 (4.6) 2 (4.0)
Vertigo 4 (2.6) 1 (1.9) 5 (3.2) 4 (7.7) 3 (2.0) 1 (2.0)
Arthralgia 4 (2.6) 1 (1.9) 3 (1.9) 0 3 (2.0) 3 (6.0)
Cough 1 (0.6) 1 (1.9) 2 (1.3) 0 2 (1.3) 4 (8.0)
Abdominal pain 1 (0.6) 1 (1.9) 2 (1.3) 3 (5.8) 1 (0.7) 0
PGBH, pregabalin high dose (450–600mg/d); PBO, placebo; PGBL, pregabalin low dose (150–300mg/d); LOR, lorazepam 3–4mg/d.
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also add to the existing literature on the short-term
(Feltner et al., 2003; Pande et al., 2003; Pohl et al., 2005;
Rickels et al., 2005; Montgomery et al., 2006) and
long-term (Feltner et al., 2008) efﬁcacy of pregabalin in
GAD. Although the study was not designed or powered
for between-drug comparisons (i.e. lack of non-inferiority
testing or superiority testing among treatments), it should
be noted that the maintenance of response at 24 wk was
similar for pregabalin low dose, pregabalin high dose
and lorazepam. Further studies are needed to conﬁrm
these 24-wk comparative outcomes.
To put the improvements over time for all treatment
groups in context, characteristics of the sample popu-
lation recruited for the current study need to be taken
into account. The average duration of GAD symptoms
(2–3 yr) for the sample in the current study was consider-
ably less than that reported in many other GAD studies,
where the average duration of GAD symptoms ranged
from 11 to 14 yr (Rickels et al., 2005; Feltner et al.,
2008). Not only did the active treatment groups show
maintenance of improvements in the current study, but
patients who switched to placebo at 12 wk (following a
taper period) also showed maintenance of gains when
evaluated at 24 wk. The possibility that individuals
with a less chronic history of GAD may fully maintain
gains achieved with a short-term (12 wk) course of treat-
ment (i.e. without continuation treatment) has important
clinical implications and should be addressed in future
studies.
A potential limitation of the current study is that only
responders at 6 wk were evaluated for discontinuation
effects. This protocol-driven selection of patients may
have biased the remaining sample towards low reporting
of symptoms. However, this design decision is consistent
with clinical guidelines (non-responders, after an ad-
equate period of treatment, would be treated with an
alternative agent) (National Institute of Health and Care
Excellence (NICE), 2011) and ethical principles for long-
term research studies. Also, the sample size, although
appropriate for the main objective to assess potential dis-
continuation symptoms, was not sufﬁcient for between-
group comparisons of these events. A larger sample size
or different study design is required to adequately test
for between-group differences.
In summary, the results of this study showed that preg-
abalin treatment (450–600 or 150–300mg/d) for 12 or
24 wk was not associated with clinically meaningful dis-
continuation symptoms or rebound anxiety following a
1-wk taper.
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